Supply chain dynamics continue to challenge ASC economics in 2026. Although general inflation has moderated, medical supply costs remain elevated and inconsistent across categories.

Current purchasing data indicates annual cost increases of 4 to 7 percent across surgical supplies, with certain segments experiencing significantly higher growth. Implants, biologics, and specialty pharmaceuticals remain the most volatile and least predictable cost centers.

Orthopedic implant pricing has increased approximately 6 to 10 percent over the past two years despite consolidation among major manufacturers. Biologic materials used in spine and sports medicine procedures have escalated even more sharply, with some categories rising between 12 and 18 percent.

Logistics costs have stabilized compared to peak pandemic levels but remain 15 to 25 percent above historical baselines. Intermittent shortages continue, particularly for specialized devices and single use instruments, creating operational uncertainty.

For most ASCs, supply expenses represent 25 to 35 percent of total operating costs. A relatively small 5 percent increase in supply pricing can translate into a 1 to 2 percentage point reduction in overall EBITDA margin.

Group purchasing strategies are evolving in response. Participation in optimized GPO contracts can generate savings of 8 to 15 percent, though often at the expense of surgeon choice and flexibility.

Inventory management is becoming more precise. High performing centers are reducing inventory days from 20 to 30 down to 10 to 15 through just in time procurement models. While this reduces carrying costs, it increases dependence on supply chain reliability.

Technology is improving efficiency. Real time inventory tracking and predictive ordering systems are reducing waste by 10 to 20 percent in early implementations.

Supply chain management is no longer a passive function. It is a financial discipline. Centers that actively manage vendor relationships and cost structures are preserving margin. Others are absorbing incremental cost increases without realizing the cumulative impact.